Answers go deeper than the script: questioning keeps surfacing new concrete detail behind a positive development · compa
The model's full reasoning — Q3 2022 call → NOWe need answer only YES or NO. Need evaluate both gates. Need use transcript. We need determine if there is positive current development with Q&A adding more concrete operating detail than prepared remarks, across multiple exchanges, substantive. And Gate 2: engine is company's own actions not external. Let's analyze. Call has many positive developments: Enhertu, Calquence, Tagrisso, camizestrant, Dato-DXd, Evusheld, rare disease, etc. Need find one where Q&A adds specifics. Prepared remarks already detailed. Q&A probes. Potential candidates: - Enhertu: Prepared remarks gave sales, launches, market share. Q&A: Tim Anderson asks Enhertu U.S big quarter, demand vs stocking, peak sales. Dave answers: growth from DESTINY-Breast03, HER2 low DBO4 launch, possible bolus, no stocking, still patients not receiving. This is somewhat additive but not much new specifics. Also Pascal says in-market sales, partnership. Not multiple exchanges. - Calquence: Q&A about stalking, maleate. Dave gives details. But not multiple. - Camizestrant: Q&A asks about data, adjuvant. Susan gives general, no specifics until SABCS. Not additive. - Evusheld: Q&A asks outlook, variants, next gen. Iskra gives details about immunocompromised, monitoring, next gen timeline. But not really positive current development? It's about uncertainty. - Rare disease: Marc discusses Ultomiris, myasthenia gravis, factor D. Q&A asks about Ultomiris MG launch and factor D. Marc gives some specifics: launched May 2022, conversion and naive patients, factor D. But not multiple exchanges. - R&I portfolio: Q&A asks about medium term, Ruud/Mene/Pascal give pipeline. Not current. - China: Q&A asks about post-COVID, Leon gives details about channels, 11/11, etc. But not a positive development? It's about managing COVID. - Nirsevimab: Q&A asks about comparison to maternal vaccine, administration. Iskra gives detailed comparison, but not necessarily new operating detail about current development? It's about product attributes. - Dato-DXd: Q&A asks biomarker, Susan gives details. But not current development? It's pipeline. - Tagrisso adjuvant: Q&A asks awareness, Dave gives details about educational process, screening. Some additive but not multiple. - Gross margin, FX: financial housekeeping. Need find one where across multiple exchanges management adds fresh specifics.
The model's full reasoning — Q1 2024 call → NOWe need answer only YES or NO. Need evaluate both gates using transcript. We need determine if there is positive current development with Q&A adding more concrete operating detail than prepared remarks, and engine is company-created. Let's analyze transcript. Prepared remarks highlight strong Q1 growth, pipeline, approvals. Q&A topics: guidance, oral GLP-1, PCSK9, Truqap launch, Dato-DXd, Farxiga/Symbicort US, Airsupra, etc. Need find positive current development where Q&A adds specifics. Candidates: Truqap launch? Prepared remarks: "strong Truqap adoption... achieving $50 million in Q1 total revenues." Q&A: Dave answers on Truqap: launch feedback, testing rates >60%, displacing previous standard, late line bolus, inclusion criteria comparison, potential multi-blockbuster. This adds some specifics but mostly strategic. Is it multiple exchanges? Only one question about Truqap. So not multiple exchanges. Airsupra: Prepared remarks: 18k HCPs prescribed, 65k scripts, share by allergists/pulmonologists, introductory discounts. Q&A: Ruud says unique product, market size 35 million inhalers, blockbuster potential, Middle East launch. Adds market size and future plans, but not much current operating detail beyond prepared. One exchange. Farxiga/Symbicort US: Prepared remarks mention Farxiga strong, generic launch, Symbicort strong despite generics. Q&A: Ruud explains authorized generic, list price, script volume, but says won't split. Adds some detail but not much new concrete. One exchange. Wainua: Prepared remarks: first revenues, good uptake, new to class and switched. Q&A: Sharon highlights cardiac data from NEURO-TTRansform, CARDIO-TTRansform trial size, timing. But that's about pipeline, not current launch operations. Not really. Dato-DXd: Prepared remarks mention pipeline, TROPION-Lung? Q&A: Susan explains confidence in new Phase 3 programs, combinations. But this is future development, not current business going well? It's about trials initiated, not current revenue. Oral GLP-1/PCSK9: Prepared remarks mention Phase 2b studies later this year. Q&A: Sharon says data at upcoming conference, competitive position, combinations. But no concrete current operating detail; it's pipeline. Need identify a positive current development that analysts probe and management adds substantive specifics across multiple exchanges.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| MNDY | monday.com Ltd. | Q4 2024 | 2024-05-15 | A |
| ZLAB | Zai Lab Limited | Q1 2024 | 2024-05-09 | B |
| YOU | Clear Secure, Inc. | Q1 2024 | 2024-05-08 | C+ |
| STIM | Neuronetics, Inc. | Q1 2024 | 2024-05-07 | B |
| CMG | Chipotle Mexican Grill, Inc. | Q1 2024 | 2024-04-24 | A |
| CSGP | CoStar Group, Inc. | Q1 2024 | 2024-04-23 | B+ |
| SAP | SAP SE | Q1 2024 | 2024-04-22 | B |
| AREC | American Resources Corporation | Q4 2023 | 2024-03-28 | F |
| QRHC | Quest Resource Holding Corporation | Q4 2023 | 2024-03-12 | C+ |
| ALKT | Alkami Technology, Inc. | Q4 2023 | 2024-03-02 | A |
| MCW | Mister Car Wash, Inc. | Q4 2023 | 2024-02-21 | D |
| TYL | Tyler Technologies, Inc. | Q4 2023 | 2024-02-15 | C+ |
| GDDY | GoDaddy Inc. | Q4 2023 | 2024-02-13 | B+ |
| SYY | Sysco Corporation | Q2 2024 | 2024-01-30 | B+ |
| STLD | Steel Dynamics, Inc. | Q4 2023 | 2024-01-24 | C+ |
| CSPI | CSP Inc. | Q4 2023 | 2023-12-12 | D |
| ATXS | Astria Therapeutics, Inc. | Q3 2023 | 2023-11-13 | C |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| VCEL | Vericel Corporation | Q3 2023 | 2023-11-08 | A |
| SG | Sweetgreen, Inc. | Q3 2023 | 2023-11-04 | D |
| CHRD | Chord Energy Corporation | Q3 2023 | 2023-11-02 | A |
| PLTR | Palantir Technologies Inc. | Q3 2023 | 2023-11-02 | B |
| REGN | Regeneron Pharmaceuticals, Inc. | Q3 2023 | 2023-11-02 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| GSK | GSK plc | Q3 2023 | 2023-11-01 | B |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| MNSO | MINISO Group Holding Limited | Q4 2023 | 2023-08-22 | A |
| PFGC | Performance Food Group Company | Q4 2023 | 2023-08-16 | B+ |
| DNUT | Krispy Kreme, Inc. | Q2 2023 | 2023-08-10 | C |
| RBLX | Roblox Corporation | Q2 2023 | 2023-08-09 | C+ |
| PODD | Insulet Corporation | Q2 2023 | 2023-08-08 | B+ |
| MVST | Microvast Holdings, Inc. | Q2 2023 | 2023-08-07 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| CIVI | Civitas Resources, Inc. | Q2 2023 | 2023-08-03 | B |
| IDT | IDT Corporation | Q3 2023 | 2023-06-05 | C |
| STIM | Neuronetics, Inc. | Q1 2023 | 2023-05-13 | B |
| VECO | Veeco Instruments Inc. | Q1 2023 | 2023-05-08 | B |
| LTH | Life Time Group Holdings, Inc. | Q1 2023 | 2023-04-25 | A |
| SCPH | scPharmaceuticals Inc. | Q4 2022 | 2023-03-22 | C+ |
| COCO | The Vita Coco Company, Inc. | Q4 2022 | 2023-03-08 | B |
| PBPB | Potbelly Corporation | Q4 2022 | 2023-03-02 | A |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| LANC | Lancaster Colony Corporation | Q2 2023 | 2023-02-02 | B+ |
| NVS | Novartis AG | Q4 2022 | 2023-02-01 | B |
| RELL | Richardson Electronics, Ltd. | Q2 2023 | 2023-01-05 | B+ |
| CUTR | Cutera, Inc. | Q3 2022 | 2022-11-05 | C |
| MUR | Murphy Oil Corporation | Q3 2022 | 2022-11-03 | B+ |
| LPX | Louisiana-Pacific Corporation | Q3 2022 | 2022-11-01 | B+ |
| INMD | InMode Ltd. | Q3 2022 | 2022-10-27 | B+ |
| INVZ | Innoviz Technologies Ltd | Q2 2022 | 2022-08-10 | D |
| FLGT | Fulgent Genetics, Inc. | Q2 2022 | 2022-08-04 | C+ |
| GTHX | G1 Therapeutics, Inc. | Q1 2022 | 2022-08-03 | D |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| TMUS | T-Mobile US, Inc. | Q2 2022 | 2022-07-27 | B+ |
| AZO | AutoZone, Inc. | Q3 2022 | 2022-05-24 | B+ |
| AXON | Axon Enterprise, Inc. | Q1 2022 | 2022-05-10 | B+ |
| VEV | Vicinity Motor Corp. | Q4 2021 | 2022-03-30 | D |
| HRTX | Heron Therapeutics, Inc. | Q4 2021 | 2022-02-28 | D |
| INCY | Incyte Corporation | Q4 2021 | 2022-02-08 | C+ |
| TMDX | TransMedics Group, Inc. | Q3 2021 | 2021-11-09 | C+ |
| ATRC | AtriCure, Inc. | Q3 2021 | 2021-11-03 | C |
| SUPN | Supernus Pharmaceuticals, Inc. | Q3 2021 | 2021-11-03 | C+ |
| ZI | ZoomInfo Technologies Inc. | Q3 2021 | 2021-11-01 | A |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| CHWY | Chewy, Inc. | Q2 2021 | 2021-09-01 | B |
| VVV | Valvoline Inc. | Q3 2021 | 2021-08-06 | B+ |
| TIGO | Millicom International Cellular S.A. | Q2 2021 | 2021-07-31 | B+ |
| SAP | SAP SE | Q2 2021 | 2021-07-21 | B+ |
| UPWK | Upwork Inc. | Q3 2018 | 2018-11-11 | B+ |
| MYO | Myomo, Inc. | Q3 2018 | 2018-11-05 | C |
| CFG | Citizens Financial Group, Inc. | Q3 2018 | 2018-10-19 | A |
| UAL | United Airlines Holdings, Inc. | Q3 2018 | 2018-10-17 | B+ |
| INSP | Inspire Medical Systems, Inc. | Q2 2018 | 2018-08-12 | A |
| REI | Ring Energy, Inc. | Q2 2018 | 2018-08-09 | B |
| GAIA | Gaia, Inc. | Q2 2018 | 2018-08-06 | B+ |
| RNG | RingCentral, Inc. | Q2 2018 | 2018-08-06 | A |
| FRPT | Freshpet, Inc. | Q2 2018 | 2018-08-06 | B+ |
| TSLA | Tesla, Inc. | Q2 2018 | 2018-08-02 | B |
| OOMA | Ooma, Inc. | Q1 2019 | 2018-05-22 | A |
| ZG | Zillow Group's | Q1 2018 | 2018-05-08 | C+ |
| QLYS | Qualys, Inc. | Q1 2018 | 2018-05-02 | B+ |
| CPS | Cooper-Standard Holdings Inc. | Q1 2018 | 2018-05-02 | B |
| VRTX | Vertex Pharmaceuticals Incorporated | Q1 2018 | 2018-04-26 | C+ |
| SYK | Stryker Corporation | Q1 2018 | 2018-04-26 | B+ |
| TNC | Tennant Company | Q4 2017 | 2018-02-22 | B |
| TMUS | T-Mobile US, Inc. | Q4 2017 | 2018-02-09 | B+ |
| NICE | NICE Ltd. | Q3 2017 | 2017-11-04 | A |
| SAMG | Silvercrest Asset Management Group Inc. | Q3 2017 | 2017-11-03 | A |
| VC | Visteon Corporation | Q3 2017 | 2017-10-28 | B+ |
| PRO | PROS Holdings, Inc. | Q3 2017 | 2017-10-26 | B+ |
| SRPT | Sarepta Therapeutics, Inc. | Q3 2017 | 2017-10-26 | C+ |
| CAL | Caleres, Inc. | Q2 2017 | 2017-08-29 | B+ |
| LITE | Lumentum Holdings Inc. | Q4 2017 | 2017-08-09 | B+ |
| FRPT | Freshpet, Inc. | Q2 2017 | 2017-08-07 | B+ |
| INTU | Intuit Inc. | Q3 2017 | 2017-05-23 | B+ |
| ADAP | Adaptimmune Therapeutics plc | Q1 2017 | 2017-05-10 | D |
| ISDR | Issuer Direct Corporation | Q1 2017 | 2017-05-06 | C |
| XPO | XPO Logistics, Inc. | Q1 2017 | 2017-05-04 | B |
| SRPT | Sarepta Therapeutics, Inc. | Q1 2017 | 2017-04-28 | D |
| SAH | Sonic Automotive, Inc. | Q1 2017 | 2017-04-26 | C |
| SYK | Stryker Corporation | Q4 2016 | 2017-01-24 | C+ |
| MCS | The Marcus Corporation | Q3 2016 | 2016-10-27 | C+ |
| GSK | GSK plc | Q3 2016 | 2016-10-26 | B |
| VYGR | Voyager Therapeutics, Inc. | Q2 2016 | 2016-08-11 | A |
| SQ | Square's | Q2 2016 | 2016-08-04 | A |
| DGII | Digi International Inc. | Q3 2016 | 2016-07-28 | B |
| PAR | PAR Technology Corporation | Q1 2016 | 2016-05-04 | D |
| PM | Philip Morris International Inc. | Q1 2016 | 2016-04-19 | B+ |
RBLX · Q2 2023 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. YES The transcript shows a clear positive current development in advertising, where management's prepared remarks mention live ads, 200 activations, 19% of top 100 with ad units, and some demand exceeding supply. In the Q&A, they add fresh specifics like pricing strategy (gentle now, floating later), new ad unit types, 12% of top 100 using portals, demand in 17-24 female cohort, self-serve options, and brand volume challenges. These details are operational and additive across multiple exchanges, meeting GATE 1 criteria. For GATE 2, advertising is driven by Roblox's own creation and control: 200 activations, portal ad units, self-serve platform, and rollout execution. It's not reliant on external industry tailwinds but on their platform improvements and brand engagement. This satisfies the primary engine condition.
SG · Q3 2023 → YESThe task is to evaluate two gates based on the Sweetgreen earnings call transcript and return YES only if both gates are YES, otherwise NO. YES The transcript shows a clear positive current development in Infinite Kitchen, with management's Q&A responses adding substantial new operational details—such as first-unit performance, customer experience improvements, margin leverage, AUV targeting, retrofit opportunities, and throughput optimizations—that go beyond the prepared remarks' high-level plans. This satisfies Gate 1 criteria for additive, substantive detail across multiple exchanges. For Gate 2, Infinite Kitchen is a proprietary technology the company developed and controls, with momentum driven by its own execution, customer adoption, and operational refinements rather than external tailwinds, making it the primary engine.
ALKT · Q4 2023 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. YES The transcript shows a clear positive current development in the bank's market progress and add-on sales momentum, with Q&A providing substantial new operational details like specific backlog numbers, implementation timelines, product adoption rates, and customer-specific challenges that go beyond the prepared remarks. For GATE 2, the primary engine is Alkami's own platform, cloud-native architecture, and execution on replacements of legacy systems, which would largely continue even if external conditions shifted, as the company is actively winning share through its controlled rollout and product improvements.